Trials / Sponsors / Spark Therapeutics, Inc.
Spark Therapeutics, Inc.
Industry · 15 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Withdrawn | Study of a Gene Therapy Treatment for Hemophilia A Hemophilia A | Phase 3 | 2024-03-13 |
| Active Not Recruiting | A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2 | Phase 1 / Phase 2 | 2020-10-01 |
| Completed | Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pomp Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2 | N/A | 2019-06-12 |
| Completed | Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited | Phase 1 / Phase 2 | 2019-01-30 |
| Completed | Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders | — | 2019-01-21 |
| Completed | A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy | — | 2019-01-10 |
| Active Not Recruiting | Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A Hemophilia A | — | 2018-08-14 |
| Completed | A Gene Transfer Study for Hemophilia A Hemophilia A | Phase 1 / Phase 2 | 2017-01-26 |
| Active Not Recruiting | Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2) Inherited Retinal Dystrophy Due to RPE65 Mutations | — | 2015-06-01 |
| Completed | Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations Choroideremia, CHM (Choroideremia) Gene Mutations | Phase 1 / Phase 2 | 2015-01-15 |
| Active Not Recruiting | Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis | Phase 3 | 2012-10-01 |
| Terminated | Hemophilia B Gene Therapy With AAV8 Vector Hemophilia B | Phase 1 | 2012-10-01 |
| Active Not Recruiting | Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 Leber Congenital Amaurosis | Phase 1 / Phase 2 | 2010-11-01 |
| Completed | Safety Study in Subjects With Leber Congenital Amaurosis Leber Congenital Amaurosis | Phase 1 | 2007-09-01 |
| Completed | LTFU for Gene Transfer Subjects With Hemophilia B Hemophilia B | — | 2007-08-01 |